Enzymatica completes acquisition of Zymetech and includes new board members and representative to the nomination committee
Enzymatica AB (publ) ("Enzymatica") has today completed the acqusition of Zymetech and taken ownership of 99.5 percent of the shares in Zymetech ehf. ("Zymetech") for a purchase price of approximately SEK 76 million through an issue in kind of 20,905,942 new shares and 3,982,084 new warrants in Enzymatica. Through the issue in kind, Enzymatica's share capital increases to SEK 1,834,695 divided into 45,867,380 shares. In connection therewith, two new board members and one new representative to the nomination committee will take up office.
Enzymatica has today completed the acquisition and became the owner of 99.5 percent of the shares in the Icelandic company Zymetech, in accordance with previous press releases. The purchase price for the Zymetech shares amounts to approximately SEK 76 million, based on a share price of 3.45 SEK per share, and has been paid through an issue in kind of 20,905,942 new shares and 3,982,084 new warrants in Enzymatica. The issue in kind increases Enzymatica's share capital to SEK 1,834,695 divided into 45,867,380 shares.
The acquisition and the issue in kind were approved at an extra general meeting on 15 February 2016. As a result of the completion of the acquisition, Guðmundur Pálmason assume a position in the nomination committee of Enzymatica, and Guðmundur Pálmason and Sigurgeir Guðlaugsson assume positions at the board of directors of Enzymatica until the end of the next annual general meeting, in accordance with the decision of the extra general meeting on 15 February 2016.
Necessary registrations with the Swedish Companies Registration Office and Euroclear Sweden AB will be finalized during the upcoming weeks.
For further information, contact:
Fredrik Lindberg, CEO Enzymatica AB
Phone: 0708-86 53 70 | E-mail: firstname.lastname@example.org
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.
Enzymatica's certified adviser is Erik Penser Bankaktiebolag.